The abnormally low wall shear stress locations correlate with the development of stenosis in the singular case that is tracked in time for a period of one year. (C) 2014 IPEM. Published by Elsevier Ltd. All rights reserved.”
“RATIONALE AND OBJECTIVES: All grants and manuscripts bearing the Canadian Critical Care Trials Group name are submitted

for internal peer review before submission. The authors MK 1775 sought to formally evaluate authors’ and reviewers’ perceptions of this process. METHODS: The authors developed, tested and administered two electronic nine-item questionnaires for authors and two electronic 13-item questionnaires for reviewers. Likert scale, multiple choice and

free-text responses were used. RESULTS: Twenty-one of 29 (72%) grant authors and 16 of 22 (73%) manuscript authors responded. Most author respondents were somewhat or very satisfied with the turnaround time, quality of the review and the review process. Two-thirds of grant (13 of 20 [65%]) and manuscript authors (11 of 16 [69%]) reported one or more successful submissions after review. Changes made to grants based on reviews were predominantly editorial and involved the background, rationale, significance/relevance and the methods/protocol sections. Twenty-one of 47 (45%) grant reviewers and 32 of 44 (73%) manuscript reviewers responded. Most reviewer respondents reported a good to excellent overall impression of the review process, good fit between their expertise

and interests NVP-BSK805 nmr and the grants reviewed, and ample KPT-8602 mouse time to review. Although most respondents agreed with the current nonblinded review process, more grant than manuscript reviewers preferred a structured review format. CONCLUSIONS: The authors report a highly favourable evaluation of an existing internal review process. The present evaluation has assisted in understanding and improving the current internal review process.”
“dl-Praeruptorin A (Pd-Ia) is the major active constituent of the traditional Chinese medicine Peucedanum praeruptorum Dunn. Recently it has been identified as a novel agent in the treatment and prevention of cardiovascular diseases. Accordingly, we investigated the metabolism of Pd-Ia in rat liver microsomes. The involvement of cytochrome P450 (CYP) and CYP isoforms were identified using a CYP-specific inhibitor (SKF-525A), CYP-selective inhibitors (a-naphthoflavone, metyrapone, fluvastatin, quinidine, disulfiram, ketoconazole and ticlopidine) and CYP-selective inducers (phenobarbital, dexamethasone and beta-naphthoflavone). Residual concentrations of the substrate and metabolites were determined by HPLC, and further identified by their mass spectra and chromatographic behavior.